Comparing Palliative Radiotherapy With or Without Carboplatin (NCT03637335) | Clinical Trial Compass
TerminatedPhase 3
Comparing Palliative Radiotherapy With or Without Carboplatin
Stopped: The study was stopped due to insufficient recruitment.
France26 participantsStarted 2015-08-17
Plain-language summary
The study population has locally advanced or metastatic bronchial or head and neck cancer.
This study assesses the value of concomitant chemo/radiotherapy with carboplatin daily during metastatic radiotherapy versus radiotherapy alone.
The realization of a systemic treatment during the radiotherapy could make it possible to obtain a benefit on the control of the evolution of the metastases and thus of the pains generated, as well as on the quality of life of the patients. In addition, a benefit in overall survival is possible.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with locally advanced or metastatic bronchial or head and neck cancer
* Patient require palliative radiotherapy
* Age ≥ 18 years
* PS ≤ 2
* Obtaining the signed written consent of the patient
* Patient affiliated to a social security scheme
Exclusion Criteria:
* Other chemotherapy or targeted therapy
* Prior radiation
* Patients with thrombopenia \< 100 000
* Patients with neutropenia \< 2000
* Patients with renal clearance \< 20 mL/min
* Known hypersensitivity to platinum salt
* Treatment with phenytoin or fosphenytoin
* In previous three months, a vaccination against yellow fever, live vaccin or live attenuated vaccine
* Unchecked diabetes
* hemorrhagic tumor
* Refusal of participation or inability to issue informed consent
* Person deprived of liberty or adult under guardianship
* Minor patients, pregnant or lactating women
* Participation in other interventional study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Local progression-free survival of chemo radiotherapy compared with placebo-associated radiotherapy